Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
News
NICE nod for Allergan’s Truberzi for IBS-D
Cost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments.
Revlimid boosts survival in myeloma patients post-transplant
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
CRUK brings commercialisation arm in-house
Cancer Research UK has brought its commercialisation arm, Cancer Research Technology (CRT), together with its research funding teams to form a new in-house division called Research and Innovation.
DH creates new role to streamline pharma costs
Steve Oldfield will be the Department’s first chief commercial officer
EU OKs first-line use of AZ’ Faslodex
EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
Final NHS nod for Allergan’s Ozurdex, AbbVie’s Humira in uveitis
Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids.
AZ, Merck link to develop and commercialise cancer drugs
In a bumper news day for AstraZeneca, the firm announced a deal with Merck & Co to co-develop and co-commercialise Lynparza and selumetinib for multiple cancer types, second-quarter results in line with expectations, initial trial data showing the failure of Imfinzi to boost PFS in lung cancer patients, and other trial data in lung cancer showing the success of Tagrisso in improving PFS.
Have your marketers entered Marketer of the Year 2017 yet?
Entrants so far have come from Shire, Bayer, AbbVie, Eisai Europe, Novartis, GSK, MSD, Lundbeck, HFA Healthcare Products, Sandoz and Bristol-Myers Squibb Pharmaceuticals among others. Don’t miss out on this crucial opportunity to identify and benchmark talent within your organisation against others in the industry.
EU nod for Chiesi’s COPD therapy
European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.
US, EU filings for Eisai’s lenvatinib in liver cancer
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).
NICE backs Roche’s Gazyvaro for follicular lymphoma
The National Institute for Health and Care Excellence has issued final draft guidance recommending that use of Roche’s Gazyvaro to treat follicular lymphoma be funded for NHS use via the Cancer Drug Fund.
Lilly, Nektar to co-develop new immunotherapy
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
RCGP warns that GP access is set to worsen
In just five years patients across England could be waiting more than a week for an appointment with a GP or practice nurse on more than 100 million occasions, according to a new projection by the Royal College of GPs.
